Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01663766
Other study ID # IM-T-IMMU-115-03
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date December 2013
Est. completion date March 2015

Study information

Verified date September 2020
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males or non-pregnant, non-lactating females, = 18 years of age - Able to understand and willing to sign informed consent. - Histologically confirmed hematologic malignancy that is deemed best treated by RIC allogeneic SCT, including: - Acute myeloid or lymphoblastic leukemia (AML, ALL) with < 5% blasts in the bone marrow - Myelodysplastic syndrome and intermediate-2 or high-risk IPSS score with < 5% blasts in the bone marrow - Chronic myelogenous leukemia failing to respond to at least two different tyrosine kinase inhibitors - Multiple myeloma that has relapsed following autologous stem cell transplant - Follicular lymphoma (grades 1, 2, or 3a by WHO criteria) or monocytoid lymphoma that has relapsed following at least two prior chemotherapy regimens and with either no lymph node groups = 3 cm or with a = 50% reduction in estimated lymph node diameter with most recent salvage therapy - Diffuse large B-cell NHL that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue) and is still sensitive to chemotherapy by virtue of a PR or CR following most recent salvage chemotherapy - Transformed follicular lymphoma that has achieved a PR or CR following chemotherapy - Mantle cell lymphoma that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue) - CLL/SLL/PLL that meets one of the following: - del (17p13.1) in first remission - Response no better than a PR with chemoimmunotherapy or relapse within 2 years of chemoimmunotherapy - Richter's transformation - Complex karyotype - At least 4 weeks beyond prior chemotherapy (excluding steroids), antibody therapy, radiation, or radioimmunoconjugate therapy, and with any kinase inhibitors discontinued at least one week prior to starting the conditioning regimen. - ECOG performance status = 2 - Life expectancy of greater than 3 months - Adequate organ function measured by the following within seven days of beginning conditioning: - AST (SGOT) = 3.0 x institutional upper limit of normal (IULN) - Total bilirubin = 1.5 xIULN unless due to Gilbert's disease - Creatinine = 2.0 mg/dL OR creatinine clearance = 50 mL/min - DLCO > 40% with no symptomatic pulmonary disease - LVEF by echocardiogram or MUGA of at least 30% - Women of child bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. - Matched (8/8) related or matched unrelated donor identified. Haploidentical or umbilical cord grafts are not allowed. - Donor willing to donate peripheral blood stem cells and meets institutional criteria for stem cell donation. Exclusion Criteria: - Prior allogeneic stem cell transplant - Patients requiring a myeloablative conditioning regimen - Patients best served by a bone marrow transplant are not eligible as this study will be restricted only to peripheral stem cells. - No suitable donor identified - Prior anaphylactic response or Grade 4 infusion reaction to milatuzumab - Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Patients with active hepatitis B infection are not eligible. Patients with a history of hepatitis B (surface antigen or core antibody positive) must take lamivudine or equivalent during study therapy and for one year after completion of milatuzumab. - LVEF < 30% - Seropositivity for HIV or Hepatitis C - Patients with known CNS lymphoma are excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. - Active secondary malignancies with the exception of non-melanomatous skin cancers or low risk prostate cancer under observation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
milatuzumab
Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Gilead Sciences Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary All patients administered any dose of study drug will be included in the evaluation of safety Safety will be measured by physical examinations and hematology and chemistry blood tests. Cardiac safety will be done using MUGA scans or echocardiograms. These assessments will be done routinely during treatment and up to 30 days after treatment and any change from baseline will be assessed. Long term safety will be assessed every 3 months after that for up to 1 year; any change from baseline will be assessed. Safety will be assessed by measuring the change from baseline during 7 days of treatment and up to 30 days after treatment
Secondary Determine the therapeutic efficacy of milatuzumab in this patient population Acute GVHD will be assessed at days +30 and +100 by laboratory testing. Chronic GVHD assessment will be performed at days +100, +270 & +365 after stem cell transplant. Efficacy will be assessed 30 days after treatment.
See also
  Status Clinical Trial Phase
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT01200355 - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Phase 4
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT02057185 - Occupational Status and Hematological Disease
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Completed NCT03941769 - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Phase 1/Phase 2
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT02262312 - Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome Phase 0
Completed NCT02188290 - Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation N/A
Recruiting NCT02330692 - Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
Completed NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Phase 1